Page 3 - Mankind Pharma

Acquisition of BSV to aid future growth of Mankind Pharma: V-C Juneja

The acquisition of Bharat Serums and Vaccines would add a lot of value, aiding future growth of Mankind Pharma, according to Vice Chairman and Managing Director Rajeev Juneja. On July 25, Mankind had announced that it will fully acquire Bharat Serums and Vaccines (BSV) from Advent International for an enterprise value of around Rs 13,630 crore. "One thing should be very clear, this acquisition is not to really add some kind of revenue, but to add a lot of value, future growth, entry barrier, super specialty business in Mankind," Juneja said in an analyst call. Whatever the company is paying for BSV, it is very relevant as the company has "so much of value" with well established business, he said. The acquisition is in line with the company's strategy of buying high entry barrier businesses, he stated. The buyout will solidify Mankind's position with complementary drug portfolio and extensive reach to target rapidly growing highly under-penetrated markets, especially in fertility,

Mankind Pharma Q1 results: Profit up 9.9% at Rs 543 cr; revenue rises 12%

Mankind also announced a rise in its prescriber penetration to 83.2 per cent in Q1 FY25, from 82.7 per cent in the same quarter last financial year

BSV portfolio can touch Rs 5K cr in 3-4 yrs: Mankind Pharma's Rajeev Juneja

'We don't want to get into exports with generic or me-too products. We always wanted products with a high level of entry barriers and complexity'

Mankind Pharma to lead in Indian women's health market after BSV deal

Deal opens doors to overseas markets with low competition

Mankind Pharma acquires Bharat Serums and Vaccines for Rs 13,600 crore

More than 2,500 BSV employees will be joining Mankind

Mankind Pharma frontrunner to acquire Bharat Serums in $1.5 bn deal

Mankind Pharma rose as much as 1.2 per cent following Thursday's Bloomberg News report. The shares are up about 6.5 per cent this year and 10 per cent in the past 12 months

Mankind Pharma and EQT compete to acquire BSV Group for Rs 14,000 crore

Advent International, the private equity firm currently owning BSV, appointed JP Morgan and Jefferies to facilitate the sale of the biopharma firm

Mankind Pharma inks pact with Takeda to commercialise acidity drug in India

The agreement allows Mankind Pharma to launch the novel drug for treating Gastroesophageal Reflux Disease

Mankind Pharma rallies 5% after 3.7 mn shares change hands via block deal

Mankind Pharma, the domestic pharmaceutical major's stock price surged up to 5.27 per cent at Rs 2,215 per share on the BSE in Wednesday's intraday trade

Stocks to watch, July 10: Angel One, Emcure Pharma, Mankind Pharma, M&M

Stocks to watch on July 10: Emcure Pharmaceuticals' shares are scheduled to make their debut on the stock exchanges on Wednesday

Dr Reddy's Laboratories, Warburg Pincus, EQT frontrunners to buy BSV

Advent looking to exit 4 years after it picked up majority stake in biopharma firm

Mankind Pharma open to acquisitions; board okays Rs 7,500 cr fundraise

The drug maker was reportedly interested in buying private equity (PE) firm Advent International's stake in Mumbai-based biopharma firm Bharat Serums and Vaccines (BSV)

M&M, Berger Paints, Mankind Pharma among six stocks to monitor on May 16

At 6:40 AM, GIFT Nifty futures were up by 90 points, trading at 22,377.50 levels compared to Nifty50 futures, indicating a gap-up opening for the stock exchanges

Mankind Pharma Q4 results: Net profit up by 62%, revenue rises by 18.9%

Mankind's revenue from operations rose to Rs 2,441 crore in Q4 FY24, an 18.9 per cent Y-o-Y rise from Rs 2,052 crore reported in Q4 FY23

Q4 FY24 results: RVNL, MOIL, Biocon among 84 firms to post earnings today

Q4 FY24 company results: Dixon Technologies, Jindal Stainless, Power Finance Corporation, Thomas Cook will also release their financial results

Mankind Pharma in fray to acquire Advent's stake in Bharat Serums: Report

Mankind Pharma's stock surged 3.11 per cent on BSE on Tuesday

Indus Towers, Bosch: Stocks that may enter MSCI Standard index on May 15

As of May 13, 2024, India's weight in the MSCI Emerging Market Index stood at around 18 per cent, a considerable rise from approximately 8 per cent in early 2020

Indus Towers, Sundaram, Mankind Pharma likely to be added to MSCI index

Nuvama has identified about a dozen "high conviction" domestic stocks that could get added to the index

PGIM India MF launches retirement fund; StanChart offers 7.5 mn shares

Standard Chartered Bank is offering up to 7.5 million shares in Central Depository Services India (CDSL) in a placement

Mankind Pharma slips 4% on Beige's likely 3% stake sale via block deal

According to media reports, Beige Ltd, an affiliate of private equity firm ChrysCapital, was looking to offload 2.90 per cent stake in the drugmaker through block deals